Cytogen granted summary judgment of non-infringement of prostate cancer patent.
Cytogen Corporation (Princeton, NJ) announced that its motion for summary judgment motion for summary judgment n. a written request for a judgment in the moving party's favor before a lawsuit goes to trial and based on recorded (testimony outside court) affidavits (or declarations under penalty of perjury), depositions, admissions of fact, answers of non-infringement of all asserted claims of United States Patent 4,460,559 (the '559 Patent) has been granted by United States District Judge Anne E. Thompson. That ruling also denied the motion by plaintiffs Milton D. Goldenberg and Immunomedics, Inc. for summary judgment of infringement. Since the '559 patent was the only patent asserted by plaintiffs, Judge Thompson ruled that the case is dismissed. Immunomedics has 30 days to appeal the decision.
The suit, filed in the United States District Court United States District Court
In the U.S., any of the 94 trial courts of general jurisdiction in the federal judicial system. Each state, as well as the District of Columbia and the Commonwealth of Puerto Rico, has at least one federal district court. of New Jersey, alleged that Cytogen's ProstaScint, a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer, infringed the '559 Patent.
Cytogen Corporation is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets proprietary and licensed oncology products through its in-house specialty sales force: ProstaScint (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer) and NMP NMP New Millennium Program (NASA)
NMP National Military Park (National Park Service)
NMP Network Management Protocol
NMP Not My Problem 22 BladderChek (a point-of-care, in vitro diagnostic test for bladder cancer). Cytogen has also developed Quadramet, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer, for which the company receives royalties on product sales through Berlex Laboratories, the United States affiliate of Schering AG Germany, which markets the product in the United States. Cytogen has exclusive United States marketing rights to Combidex, an ultrasmall superparamagnetic iron oxide The introduction to this article provides insufficient context for those unfamiliar with the subject matter.
Please help [ improve the introduction] to meet Wikipedia's layout standards. You can discuss the issue on the talk page. contrast agent for magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. of lymph nodes. Cytogen's pipeline comprises product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA PSMA Public Sector Mapping Agencies (Australia)
PSMA Prostate-Specific Membrane Antigen
PSMA Power Sources Manufacturers Association
PSMA Pakistan Sugar Mills Association
PSMA Professional Services Management Association (prostate specific membrane antigen) technology, which was exclusively licensed from Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New . Cytogen also conducts research in cell signaling through its AxCell Biosciences research division in Newtown, PA.